Introduction
Glucocorticoids are drugs endowed with a potent anti-inflammatory effect, although the mechanism of action is not completely understood. It has been proposed that they inhibit phospholipase a 2 (PLA2) activity and thus prevent eicosanoid formation. The inhibitory effect of glucocorticoids on PLA2 appears to be mediated by inducible inhibitory proteins called lipocortins (tCTs) . After the cloning and identification of the gene of lipocortin 1 (LCT-1) it has been shown that they belong to a larger family of proteins (annexins) with calcium and phospholipid binding properties, whose precise biological role is not yet clear. 2 In vivo anti-inflammatory activity has been reported in experimental inflammation for recombinant LCT-13 and for a purified 36 kDa protein immunologically related to lipocortin 5 (LCT-5). 4 Recently, by aligning the sequences of LCT-5 and uteroglobin (another anti-PLA2 protein) a nine aminoacid conservative region has been identified. The peptide deriving from this region of LCT-5 (amino acids [204] [205] [206] [207] [208] [209] [210] [211] [212] has shown anti-inflammatory activity both in vitro and in vivo suggesting that it could represent the active site of the anti-inflammatory effect of In this paper the anti-inflammatory mechanism of LCT-1 and LCT-5 has been investigated both in vitro and in vivo. The results confirm that the two (C) 1993 Leukocyte migration was not significantly modified by i.v. injection of the sham protein (Fig. 3) .
Discussion
The present results indicate that LCT-1 and LCT-5 possess anti-inflammatory activity with some differences. Both proteins inhibited leukocyte migration in vivo during zymosan induced pleurisy whereas only LCT-5 caused a dose dependent inhibition of PMN chemotaxis in vitro. On the other hand, LCT-5 was less potent than LCT-1 in reducing PGE2 release from activated macrophages and was ineffective in reducing carrageenin induced paw oedema where LCT-1 gave a significant and long-lasting inhibition.
The anti-inflammatory profile of LCT-1 is consistent with inhibition of PLA2 activity. In fact 
